×
About 6,020 results

ALLMedicine™ Leukemias Center

Research & Reviews  1,824 results

Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precu...
https://doi.org/10.1038/s41375-021-01502-z
Leukemia Seyfried F, Stirnweiß FU et. al.

Jan 16th, 2022 - Targeting BCL-2, a key regulator of survival in B-cell malignancies including precursor B-cell acute lymphoblastic leukemia, has become a promising treatment strategy. However, given the redundancy of anti-apoptotic BCL-2 family proteins (BCL-2, B...

Oncogenic TYK2P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4...
https://doi.org/10.3324/haematol.2021.279848
Haematologica Woess K, Macho-Maschler S et. al.

Jan 14th, 2022 - Tyrosine kinase 2 (TYK2) is a member of the Janus kinase/signal transducer and activator of transcription pathway, which is central in cytokine signaling. Previously, germline TYK2 mutations have been described in two patients developing de novo T...

The Psychosocial Burden of Families with Childhood Blood Cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744617
International Journal of Environmental Research and Publi... Borrescio-Higa F, Valdés N

Jan 12th, 2022 - Cancer is the second leading cause of death for children, and leukemias are the most common pediatric cancer diagnoses in Chile. Childhood cancer is a traumatic experience and is associated with distress, pain, and other negative experiences for p...

Transcription factor c-Myb: novel prognostic factor in osteosarcoma.
https://doi.org/10.1007/s10585-021-10145-4 10.4103/0971-5851.203513 10.1016/j.ejca.2018.11.027 10.1016/j.anndiagpath.2020.151654 10.3390/medsci7020028 10.3389/fgene.2020.00789 10.1038/nrc2439 10.1111/j.1440-169X.2011.01287.x 10.1007/s00223-016-0219-2 10.1038/leu.2012.225 10.1002/gcc.20378 10.1038/s41389-021-00309-y 10.1002/hed.25597 10.1007/s13277-016-4797-4 10.1186/1756-9966-31-100 10.1093/nar/gky354 10.1038/nprot.2013.143 10.1016/j.neo.2021.01.002 10.1016/j.jsbmb.2015.04.019 10.1007/s11064-019-02925-y 10.14806/ej.17.1.200 10.1093/bioinformatics/bts635 10.1093/bioinformatics/btt656 10.1186/s13059-014-0550-8 10.1093/nar/gkz401 10.1186/s12964-020-00559-0 10.1093/hmg/ddi312 10.1111/his.14265 10.1007/s13277-016-4956-7 10.1155/2012/937506 10.1038/s41467-019-14190-2 10.1038/ncomms12073 10.3390/ijms20184354 10.1074/jbc.REV118.002804 10.1038/onc.2017.392 10.1073/pnas.1102826108 10.1155/2014/813067 10.1111/cas.14141 10.1080/2162402X.2016.1149667 10.1016/S0002-9440(10)64080-1 10.1007/s12094-013-1009-1 10.1007/s12094-013-1010-8 10.2741/3738 10.4161/cc.10.23.18346 10.1186/bcr3580 10.1038/s41598-019-48051-1 10.1016/j.scr.2014.08.002 10.1002/mc.22934 10.1158/0008-5472 10.1021/acs.jproteome.9b00641 10.1371/journal.pone.0133280 10.1074/jbc.M113.500264 10.1002/cbf.1808 10.1038/s41388-019-0789-3 10.1038/s41598-020-63396-8 10.1038/s41389-020-0194-3 10.1016/j.cellsig.2016.04.007 10.1038/cdd.2009.94 10.1074/jbc.REV119.007759 10.1002/1878-0261.12085 10.1038/s41388-019-0905-4 10.1016/j.semcancer.2015.02.003 10.1016/j.drudis.2021.07.007 10.1007/978-3-030-43085-6_8 10.1016/j.bbamcr.2015.11.017 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q 10.1161/01.res.80.5.617 10.3389/fphys.2016.0016 10.1186/1752-0509-6-50 10.1159/000399103 10.1023/a:1006623001465 10.1016/j.canlet.2020.01.039 10.1016/j.canlet.2021.07.010 10.1158/1535-7163.MCT-16-0185 10.1182/blood-2015-09-668632 10.1016/j.exphem.2016.12.003 10.1038/leu.2017.317 10.1038/cti.2014.29 10.1111/cas.12156
Clinical & Experimental Metastasis; Říhová K, Dúcka M et. al.

Jan 8th, 2022 - The transcription factor c-Myb is an oncoprotein promoting cell proliferation and survival when aberrantly activated/expressed, thus contributing to malignant transformation. Overexpression of c-Myb has been found in leukemias, breast, colon and a...

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

Jan 5th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

see more →

Guidelines  2 results

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  223 results see all →

Clinicaltrials.gov  81 results

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

Jan 5th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
https://clinicaltrials.gov/ct2/show/NCT02781883

Jan 4th, 2022 - Improvement of clinical benefit in fragile AML patients while maintaining tolerability is an important area of further clinical development. Modern aggressive combination chemotherapy can induce CR in a significant proportion of patients with prev...

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Dec 14th, 2021 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT00380653

Dec 13th, 2021 - The goal of this study is to find the highest tolerable dose of sapacitabine that can be given to patients with advanced leukemias or myelodysplastic syndromes.

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
https://clinicaltrials.gov/ct2/show/NCT03761069

Dec 9th, 2021 - This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory...

see more →

News  277 results

WHO Releases First-Ever Classification for Pediatric Tumors
https://www.medscape.com/viewarticle/965773

Dec 30th, 2021 - NEW YORK (Reuters Health) - The World Health Organization has produced its first classification of pediatric tumors, and it reflects the current transition away from mostly microscopy-driven systems of classification toward molecularly-driven clas...

Emerging Data With KO-539 and Other Menin Inhibitors Generate Excitement in AML
https://www.onclive.com/view/emerging-data-with-ko-539-and-other-menin-inhibitors-generate-excitement-in-aml

Dec 22nd, 2021 - Investigational menin inhibitors like KO-539 have showcased early promise in KMT2A-rearranged and NPM1-mutated acute myeloid leukemia (AML), according to Naval Daver, MD, who added that next steps with these agents will be to develop effective man...

Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS
https://www.onclive.com/view/active-disease-icu-deferral-linked-with-covid-19-related-mortality-in-aml-all-and-mds

Dec 12th, 2021 - Mortality rates in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) who were diagnosed with COVID-19 were higher compared with non-cancer populations who had COVID-19, according to ...

Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS
https://www.medscape.com/viewarticle/964653

Dec 12th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Factors associated with the worst COVID-19-related outcomes for patients with acute leukemias and myelodysplastic syndromes include neutropenia, p...

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

see more →

Patient Education  1 results see all →